CN103185784B - Reagent device and method for detecting mycoplasma pneumonia antibody - Google Patents
Reagent device and method for detecting mycoplasma pneumonia antibody Download PDFInfo
- Publication number
- CN103185784B CN103185784B CN201110453956.3A CN201110453956A CN103185784B CN 103185784 B CN103185784 B CN 103185784B CN 201110453956 A CN201110453956 A CN 201110453956A CN 103185784 B CN103185784 B CN 103185784B
- Authority
- CN
- China
- Prior art keywords
- hole
- dilution
- sample
- fluid apertures
- reacting hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 132
- 238000000034 method Methods 0.000 title claims abstract description 58
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 title abstract description 6
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 title abstract description 4
- 239000012895 dilution Substances 0.000 claims abstract description 139
- 238000010790 dilution Methods 0.000 claims abstract description 139
- 238000001514 detection method Methods 0.000 claims abstract description 83
- 239000007788 liquid Substances 0.000 claims abstract description 52
- 102000004190 Enzymes Human genes 0.000 claims abstract description 45
- 108090000790 Enzymes Proteins 0.000 claims abstract description 45
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- 239000000758 substrate Substances 0.000 claims abstract description 31
- 239000000523 sample Substances 0.000 claims description 99
- 239000012530 fluid Substances 0.000 claims description 95
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 53
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000007789 sealing Methods 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 15
- 239000003463 adsorbent Substances 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 11
- 241000204003 Mycoplasmatales Species 0.000 claims description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 8
- 230000009977 dual effect Effects 0.000 claims description 6
- 239000012898 sample dilution Substances 0.000 claims description 6
- 239000013026 undiluted sample Substances 0.000 claims description 6
- 238000011481 absorbance measurement Methods 0.000 claims description 4
- 239000012470 diluted sample Substances 0.000 claims description 4
- 230000012447 hatching Effects 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 16
- 238000002965 ELISA Methods 0.000 abstract description 15
- 238000004458 analytical method Methods 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 36
- 229940088598 enzyme Drugs 0.000 description 35
- 230000000694 effects Effects 0.000 description 10
- 238000001467 acupuncture Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 5
- 239000002075 main ingredient Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000003547 immunosorbent Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000026676 system process Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002725 anti-mycoplasma Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical class C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005560 droplet transmission Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000006473 polyradiculopathy Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Automatic Analysis And Handling Materials Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a reagent device and a method used for detecting mycoplasma pneumonia antibodies. The reagent device has a long strip shape, and has a base body comprising 8 hole positions and a handle positioned on one end of the base body. From the end proximal to the handle, the 8 hole positions are sequentially a sample hole, an auxiliary agent hole, an enzyme conjugate hole, a substrate hole, a termination liquid hole, a dilution liquid hole, a reaction hole, and a dilution hole. According to the invention, based on a principle of enzyme-linked immunoassay, mycoplasma pneumonia antibody is detected by using the reagent device. The method is an independent single-person analysis and detection method. The device can be used in cooperation with a corresponding specific analysis instrument. During a detection process, detection reagents or samples are injected by using a full-automatic precise dosing device. The device and the method have the advantages of automatic operation, precise dosing, high detection result accuracy, high detection result precision, and wide application prospect.
Description
Technical field
The present patent application relates to a kind of reagent device and the method thereof that detect mycoplasma pneumoniae antibody, belongs to clinical immunology detection technique field.
Background technology
The pathological change of Eaton agent pneumonia is based on interstitial pneumonia, and concurrent Bronchopneumonia, is called primary atypical pneumonia sometimes.Main through droplet transmission, in 2 ~ 3 weeks latent period, the incidence of disease is the highest with teenager.Clinical symptoms is comparatively light, even at all asymptomatic, also only shows as the general respiratory symptom such as headache, pharyngalgia, heating, cough, but also have sporadic deaths to report if having.All can occur throughout the year, but many in time autumn and winter.Existing a large amount of clinical data shows now, and mycoplasma pneumoniae infection not only causes respiratory tract infectious disease, and causes many extrapulmonary complications, often involves the systems such as the heart, liver, kidney, nervous centralis, skin, blood.Skin lesion can show as maculopapule, erythema nodosum, vesicle etc.; The more common hemolytic anemia of hematological; The visible polyradiculitis of central nervous system damage, meningoencephalitis and cerebellar lesion etc.; Cardiovascular system pathology is even myocarditis and pericarditis.
Mycoplasma pneumoniae (Mycoplasma pneumonia, MP) be the pathogen of mankind's Eaton agent pneumonia, it is one of minimum microorganism that can grow on cell-free medium, mean diameter 125nm ~ 150nm, acellular wall, can grow on the agar medium containing haemocyanin and sterol, and after 2 ~ 3 weeks, bacterium colony is fried egg shape, centre is thicker, low flat around.The secretion of the main per os of mycoplasma, nose is propagated in atmosphere, causes sporadic respiratory tract infection or little popular.
It is clinical infection one of index comparatively reliably that mycoplasma pneumoniae antibody measures, and high specificity, highly sensitive.MP IgM generally starts to raise after infection for about 7 ~ 9 days, within 3 ~ 4 weeks, reaches peak, continues 4 ~ 6 months.Therefore mycoplasma pneumoniae antibody IgM positive prompting acute stage of infection, is the specific index of early diagnosis.MP IgG occurs a little later, and the duration is longer, and specificity is stronger.Its reason may be that after antigen invades body, first immune system produces IgM antibody, then occurs type conversion and produces IgG.It is reported, convalescence after infecting, MP IgG antibody titre obviously rises.IgG, IgM are simultaneously positive had represented that infection was early stage, and the initial IgM occurred not yet disappears, and IgG occurs, and antibody is in higher level, has diagnostic significance.
The common methods of clinical detection mycoplasma pneumoniae antibody comprises the method for Gold standard, indirect agglutination, enzyme linked immunosorbent assay, but these methods all also exist weak point.
One, Gold standard
Gold standard is a kind of novel immunolabelling technique being applied to antigen-antibody using collaurum as tracer label thing.According to some physical behaviors of collaurum, as high electron density, grain size, shape and color reaction, add immunity and the biological characteristics of bond, collaurum has been widely used in the fields such as immunology, histology, pathology and cell biology.
The method is quick, susceptibility is high, but its poor specificity, false positive rate is higher, and can only do qualitative detection, can not be quantitative.
Two, indirect agglutination
Soluble antigen (or antibody) is first adsorbed in the surface of the particulate carrier of suitable size, then act on corresponding antibodies (or antigen), under suitable electrolyte existent condition, there is specific agglutination phenomenon, claim indirect agglutination or passive agglutination.The method has fast, responsive, easy and simple to handle, without the need to features such as special experimental facilitiess, the mensuration of antigen or antibody can be used for.But its poor specificity, susceptibility is lower, and can only do qualitative detection, can not be quantitative.
Three, enzyme linked immunosorbent assay
Enzyme linked immunosorbent assay (ELISA) is widely used in detecting anti-mycoplasma pneumoniae antibody, but the method also also exists following weak point:
(1) use 12 × 8 types, 6 × 8 types, 8 × 12 types or complete plate 96 hole Special micro porous plate as antigen coated apparatus and reaction vessel, 12 batches, 6 batches, 8 batches can only be divided in use or whole plate once uses, cannot carry out independently, the detection of single part;
(2) reagent type that quantitative measurement is used is more, each detects reagent and all carrys out splendid attire with reagent bottle, and all need to change imbibition nozzle when often using a kind of reagent to be filled into respectively in the micropore of microwell plate, not only reagent bottle kind is many, and the operation of filling reagent is also very loaded down with trivial details;
(3) the corresponding mark to Detection Information is lacked, can only by checking that the product batch number and term of validity information detecting reagent could be understood or know to the mark of kit external packing box, and the information known is not controlled in testing process, there is very large randomness;
(4) detect reagent in testing process, be in open space, easily cause the cross pollution between various reagent and affect the accuracy of testing result;
(5) the many employing manual operationss of testing process, the dosage of reagent or sample is not very accurate, and operating process is very loaded down with trivial details and complicated, easily bust occurs, and accuracy and the precision of testing result are poor;
(6) in the quantity configuration and use of test item reagent set, item number × 48/96 person-portion is, if need detection 10 projects, then reagent configuration and use number must be 10 × 48/96 person-portions, if only have the project that a sample needs detection 10 different, also need the reagent of configuration 10 × 48/96 person-portion, there is the shortcoming of inadequate economical rationality.
Summary of the invention
Patented claim of the present invention be namely for current for above shortcomings part in the detection of mycoplasma pneumoniae antibody, a kind of reagent device and the detection method thereof that can carry out the detection of separate single person-portion are provided.
Patented claim of the present invention realizes the detection of mycoplasma pneumoniae antibody based on the principle of enzyme linked immunosorbent detection, be a kind of independently, single part, the disposable method of inspection; Further, the present patent application additionally provides the corresponding reagent device supporting to the method, plurality of reagents required for mycoplasma pneumoniae antibody enzyme linked immunosorbent detection is contained in one independently, in the reagent device of porous structure, moved abandoned detecting step by substep filling by this reagent device; Further, described reagent device can also carry out corresponding fully-automated synthesis by special immunity analysis instrument.
One of object of the present patent application is to provide a kind of reagent device detecting mycoplasma pneumoniae antibody, and this object is realized by following technical scheme:
Specifically, the reagent device of the detection mycoplasma pneumoniae antibody described in the present patent application is strip, comprise the matrix with position, eight holes and the handle being positioned at matrix one end, putting in order of position, eight holes is followed successively by sample aperture near handle end, assistant agent hole, enzyme conjugates hole, substrate hole, stop fluid apertures, dilution fluid apertures, reacting hole and dilution holes, sample to be tested is filled in sample aperture, assistant agent hole adds auxiliary reagent whenever necessary for detection, enzyme conjugates solution is filled in enzyme conjugates hole, substrate fills substrate solution in hole, stop filling stop buffer in fluid apertures, dilution is filled in dilution fluid apertures, reacting hole is flat and has high light penetrability, hole endoperidium has mycoplasma pneumoniae antigen, and to annotate liquid sample to be measured and detect reagent and cleansing solution as reaction vessel, absorbance measurement is carried out after reaction terminating, dilution holes is as Sample Dilution container, during for diluted sample.
Further, in described reagent device, when detecting mycoplasma pneumoniae antibody IgG, assistant agent hole does not add any reagent, and when detecting mycoplasma pneumoniae antibody IgM, adsorbent adds in assistant agent hole or together with dilution and adds in dilution fluid apertures.
Further, in described reagent device, assistant agent hole, enzyme conjugates hole, substrate hole, termination fluid apertures and dilution fluid apertures are coated with sealing film, sealing film mainly plays and prevent the effect of overflow in the process of transport and movement, in addition, the effect that preventing dust pollutes and strengthens stability is also played.
Further, described handle is pasted with bar code, this bar code identification has mycoplasma pneumoniae antibody to detect the relevant information of reagent and analytical equipment.
Further, described information comprises test item code, detects the sequence number etc. of reagent product batch number, the reagent term of validity, quantitative measurement standard parameter of curve/qualitative correction coefficient, enzyme linked immunoassay type, reagent and analytical equipment.
Further, described reagent device also comprises several support columns, described support column is positioned at below described reagent device matrix, is separated with position, more than one hole between adjacent supports post, and the effect of support column is physical strength in order to strengthen matrix and balance.
Further, in described reagent device, reacting hole is made up of exit orifice and endoporus, the bottom of exit orifice has bottom outlet, endoporus through bottom outlet and with bottom outlet wringing fit, leave anti-overflow chamber between exit orifice and endoporus, the effect in anti-overflow chamber is in course of reaction, if overflow, can stay in chamber, preventing pollution instrument and other reagent devices.
Further, in described reagent device, the mycoplasma pneumoniae antigen of the endoporus bag quilt of reacting hole comprises purifying and the mycoplasma pneumoniae of the mycoplasma pneumoniae of deactivation or restructuring.
Further, the mycoplasma pneumoniae of described restructuring includes but not limited to mycoplasma pneumoniae P1 recombinant protein.
It is clearly understood that, in the present patent application, in described reagent device, the size of position, each hole, shape are not limited, such as the open peristoma of position, each hole can be square or circular, the shape of its section also can be square, " U " type or " V " type, but for reacting hole, in order to obtain good light penetrability, bottom should be flat.
Further, the sample added in described sample aperture is test serum or blood plasma, and the amount added is determined according to the multiple of the size of sample aperture and the dilution of detection needs.
Described assistant agent hole is the use adding auxiliary reagent when being necessary, such as adsorbent, neutralizing agent, inhibitor, damping fluid etc.As when detecting mycoplasma pneumoniae antibody IgM, adsorbent adds and to add in dilution fluid apertures in assistant agent hole or together with dilution, its Main Ingredients and Appearance is anti-human IgG antibodies or Human fetal cardiomyocytes albumin A (SPA), to remove in testing process other materials such as specific IgG and rheumatoid factor to the interference of testing result.
Enzyme conjugates solution is added in described enzyme conjugates hole, Main Ingredients and Appearance is anti-human igg or the IgM antibody of horseradish peroxidase-labeled, the anti-human igg of alkali phosphatase enzyme mark or IgM antibody, the anti-human igg of glucose oxidase thing enzyme labeling or IgM antibody, or beta galactosidase mark anti-human igg or IgM antibody.
The substrate solution Main Ingredients and Appearance added in described substrate hole is TMB, OPD or ABTS.
TMB is as a kind of chromogen reagent of new type of safe, progressively replace the benzidine derivative of strong carcinogen biphenylamine and other carcinogenicity, be applied to the fields such as clinical assay, forensic medical examination, criminal detection and environmental monitoring, especially in biochemistry test, TMB, as the new substrate of peroxidase, obtains a wide range of applications in enzyme immunoassay (EIA) (EIA) and enzyme linked immunosorbent assay method (ELISA).
Sulfuric acid or the hydrochloric acid solution of the stop buffer Main Ingredients and Appearance added in described termination fluid apertures to be concentration be 0.1 ~ 0.5M.
The dilution Main Ingredients and Appearance added in described dilution fluid apertures is phosphate buffer, Tris damping fluid, borate buffer solution or carbonate buffer solution, and containing components such as certain density bovine serum albumin(BSA), sodium azide, for getting rid of the nonspecific interference of sample small molecular material and increasing Almost Sure Sample Stability.
Another object of the present patent application is to provide the detection method utilizing mentioned reagent device to carry out mycoplasma pneumoniae antibody, and described method comprises following step:
1) in described sample aperture, undiluted sample is added;
2) from dilution fluid apertures, drawing dilution adds in dilution holes;
3) remove the remaining liq in dilution fluid apertures, from dilution holes, draw partially liq return dilution fluid apertures;
4) from sample aperture, draw sample add in dilution fluid apertures, sample is diluted;
5) from dilution fluid apertures, imbitition adds in dilution holes, is further diluted by sample;
6) as detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole from assistant agent hole imbitition, other situations then do not need this step;
7) from dilution holes, imbitition adds in reacting hole, under the condition of 25 ~ 37 DEG C, hatches 30 ~ 60min;
8) liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
9) from enzyme conjugates hole, drawing enzyme conjugates solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, removes liquid after reaction 30 ~ 60min;
10) step 8 is repeated);
11) from substrate hole, drawing substrate solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, and reaction 10 ~ 20min;
12) from termination fluid apertures, drawing stop buffer adds in reacting hole, reads OD value in 1 ~ 10min in 450nm, or Double wavelength method measures, and wavelength coverage is at 620nm ~ 690nm.
Further, described method comprises following step:
1) in described sample aperture, add undiluted sample, volume is at least 1/4 of sample aperture capacity;
2) from dilution fluid apertures, drawing dilution adds in dilution holes, and the amount of absorption is more than 7/10 of total amount of liquid in hole;
3) remove the remaining liq in dilution fluid apertures, from dilution holes, draw partially liq according to expection extension rate and return dilution fluid apertures;
4) from sample aperture, draw sample add in dilution fluid apertures, diluted by sample, extension rate is 1 ~ 10 times;
5) from dilution fluid apertures, imbitition adds in dilution holes, and further diluted by sample, extension rate is 1 ~ 100 times;
6) as detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole from assistant agent hole imbitition, other situations then do not need this step;
7) from dilution holes, imbitition adds in reacting hole, under the condition of 25 ~ 37 DEG C, hatches 30 ~ 60min;
8) liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
9) from enzyme conjugates hole, drawing enzyme conjugates solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, removes liquid after reaction 30 ~ 60min;
10) step 8 is repeated);
11) from substrate hole, drawing substrate solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, and reaction 10 ~ 20min;
12) from termination fluid apertures, drawing stop buffer adds in reacting hole, reads OD value in 1 ~ 10min in 450nm, or Double wavelength method measures, and wavelength coverage is at 620nm ~ 690nm.
Further, described method comprises following step:
1) in described sample aperture, add sample 80 ~ 150 μ L;
2) from dilution fluid apertures, 360 μ L liquid are drawn in dilution holes with accurate charger;
3) remove the remaining liq in dilution fluid apertures, from dilution holes, draw 180 μ L liquid return dilution fluid apertures;
4) from sample aperture, 20 μ L liquid are drawn in dilution fluid apertures, the dilution of 10 times, sample with accurate charger;
5) with accurate charger from dilution fluid apertures imbitition 20 μ L in dilution holes, the dilution of 100 times, sample;
6) as detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole with accurate charger from assistant agent hole imbitition 30 μ L, other situations then do not need this step;
7) in reacting hole, at 25 ~ 37 DEG C, after hatching 60min, liquid is removed with accurate charger imbitition 100 μ L from dilution fluid apertures;
8) liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
9) react to reacting hole with the abzyme bond solution that 100 μ L horseradish peroxidase-labeled drawn by accurate charger from enzyme conjugates hole, at 25 ~ 37 DEG C, after reaction 30min, remove liquid;
10) step 8 is repeated);
11) to reacting hole, 10 ~ 15min is reacted with the tmb substrate solution that 100 μ L drawn by accurate charger from substrate hole;
12) annotate in reacting hole from the stop buffer stopping drawing fluid apertures 100 μ L with accurate charger, detects under 450nm and 630nm dual wavelength condition in 1 ~ 10min, read OD value.
Described cleansing solution comprises PBST solution, PBST solution refers to that PBS solution adds Tween-20, PBS solution refers to phosphate buffer (Phosphate Buffer Solution), osmotic pressure is similar to physiological condition, has again very strong pH surge capability, is commonly used to wash cell and the basal liquid as cell chulture, and Tween-20 is a kind of non-ionic surfactant, cell growth can have an impact, and Tween-20 has the effect of renaturation antigen, can improve specific recognition capability.
Reagent device and the method thereof of mycoplasma pneumoniae antibody is measured described in the present patent application, not only there is high specificity that other detection methods have, highly sensitive, accuracy is good, cost is lower, request for utilization is not high, operation is comparatively easy, obtain the advantage that the testing result time is short, be widely used etc., and solve many deficiencies of other detection methods, be embodied in the following aspects:
1. the detection method described in uses enzyme-linked immuno assay principle, utilize specific analytical instrument, adopt supporting special detection kit and analytical reagent device, automatically realizing mycoplasma pneumoniae antibody quantitative measurement, is a kind of completely newly, be suitable for, scheme that is practical, that detect mycoplasma pneumoniae antibody efficiently, fast;
2. it be a kind of independently, the detection reagent of single part and analytical equipment, without the need to using 12 × 8 types, 6 × 8 types, 8 × 12 types or complete plate 96 hole special enzyme-linked immune microwell plate as antigen coated articles for use and reaction vessel as general ELISA method, as long as have a sample can carry out the detection of respective items object in use and without the waste of reagent, if the quantity of sample exceedes portion, use this reagent and analytical equipment by actual sample number;
3. each is detected required reagent and is contained in the reagent wells position of an analytical reagent device by it, and detection reagent need not be carried out splendid attire with different reagent bottles respectively, not only operate very easy, and be not easy to cause bust, thus ensure the correctness of testing result;
4. it has a Special bar code to each analytical reagent device, the numerical value of bar code comprises test item code corresponding to detection, detects reagent product batch number, the reagent term of validity, quantitative measurement typical curve parameter, concrete enzyme linked immunoassay type, reagent and analytical equipment the information such as sequence number, can not arbitrarily be changed, strictly controlled during use, especially when use exceedes term of validity detection reagent, to be identified and stop and send examining report, thus the accuracy of detection can be guaranteed;
5. each detection reagent is effectively separated and seals by it, can not cause the cross pollution between various reagent and affect testing result;
6. it is a kind of analytical reagent device being exclusively used in particular analysis instrument, and annotate with full automatic accurate charger in testing process and detect reagent, cleansing solution or sample, operation automation, dosage is accurate, and accuracy and the precision of testing result are high;
7., in the quantity configuration and use of test item reagent set, all use needs to carry out being equipped with by reality, especially detecting entry, are equipped with more appropriate, there will not be super configuration and service condition.
Accompanying drawing explanation
Fig. 1 is the cross-sectional view of an embodiment of reagent device described in the present patent application;
Fig. 2 is the top plan view of embodiment described in Fig. 1;
Fig. 3 is the cross-sectional view of another embodiment of reagent device described in the present patent application;
Fig. 4 is the top plan view of reacting hole in another embodiment of reagent device described in the present patent application;
Fig. 5 and Fig. 6 is the assembling schematic diagram of endoporus and exit orifice in reacting hole in reagent device described in Fig. 4;
Wherein, 10 be matrix, 20 be handle, 30 be bar code, 40 be sealing film, 50 be support column, 11 be sample aperture, 12 be assistant agent hole, 13 be enzyme conjugates hole, 14 be substrate hole, 15 for stop fluid apertures, 16 for dilution fluid apertures, 17 be reacting hole, 18 be dilution holes, 171 be exit orifice, 172 be endoporus, 173 be anti-overflow chamber, 174 for bottom outlet.
Embodiment
Below in conjunction with concrete pick-up unit and implementation step, the reagent device described in the present patent application and detection method are conducted further description, object is in order to the public better understands technical scheme described in the present patent application instead of the restriction to described technical scheme.In fact, with identical or approximate principle, to the improvement that described reagent device carries out, comprise the change of its shape, size, material used, and the increase and decrease of corresponding construction or replacement, all within the present patent application technical scheme required for protection.
Embodiment one detects the reagent device one of mycoplasma pneumoniae antibody
As shown in Figure 1-2, the reagent device of the detection mycoplasma pneumoniae antibody described in the present patent application is strip, comprise the matrix 10 with position, eight holes and the handle 20 being positioned at matrix 10 one end, putting in order of position, eight holes is followed successively by sample aperture 11 from nearly handle 10 end, assistant agent hole 12, enzyme conjugates hole 13, substrate hole 14, stop fluid apertures 15, dilution fluid apertures 16, reacting hole 17 and dilution holes 18, sample to be tested is filled in described sample aperture 11, assistant agent hole 12 adds auxiliary reagent (as added adsorbent in assistant agent hole during detection IgM) when needing for detection, enzyme conjugates solution is added in enzyme conjugates hole 13, substrate solution is added in substrate hole 14, stop fluid apertures 15 and add stop buffer, dilution is added in dilution fluid apertures 16, reacting hole 17 is flat and has very high light penetrability, when splendid attire is colourless or Reagent blank solutions time, to the absorbance of visible ray or ultraviolet light or fluorescence close to zero, the antigen of mycoplasma pneumoniae composition has been coated with in hole, and to annotate liquid sample to be measured and detect reagent and cleansing solution as reaction vessel, absorbance measurement is carried out after reaction terminating, dilution holes 18 is as Sample Dilution container, during for diluted sample.
Further, in described reagent device, assistant agent hole 12, enzyme conjugates hole 13, substrate hole 14, termination fluid apertures 15 and dilution fluid apertures 16 are coated with sealing film 40, sealing film 40 mainly play transport and movement process in, prevent the effect of overflow, in addition, the effect that preventing dust pollutes and increases stability is also played.
Further, described handle 20 is pasted with bar code 30, this bar code 30 mark has mycoplasma pneumoniae antibody to detect the information of reagent and analytical equipment, and described information comprises test item code, detects the sequence number of reagent product batch number, the reagent term of validity, quantitative measurement standard parameter of curve/qualitative correction coefficient, enzyme linked immunoassay type, reagent and analytical equipment.
Embodiment two detects the reagent device two of mycoplasma pneumoniae antibody
As shown in Figure 3, the reagent device of the detection mycoplasma pneumoniae antibody in the present embodiment, its basic structure is identical with the reagent device in embodiment one, several support columns 50 are also comprised at described reagent device, described support column 50 is arranged in below described reagent device matrix 10, be separated with position, more than one hole between adjacent supports post 50, the effect of support column 50 is physical strength in order to strengthen matrix and balance.
Embodiment three detects the reagent device three of mycoplasma pneumoniae antibody
As Figure 4-Figure 6, for detecting the preferred embodiment of the reagent device of mycoplasma pneumoniae antibody described in the present patent application, its basic structure is identical with embodiment one or embodiment two, difference is that reacting hole 17 is detachable structure, reacting hole 17 is made up of exit orifice 171 and endoporus 172, the bottom of exit orifice 171 has bottom outlet 174, endoporus 172 through bottom outlet 174 and with bottom outlet 174 wringing fit, anti-overflow chamber 173 is left between exit orifice 171 and endoporus 172, the effect in anti-overflow chamber 173 is in course of reaction, if overflow, can stay in chamber, preventing pollution instrument and other reagent devices.
Further, the cooperation fixed form of described endoporus and exit orifice can also be that the outer wall of endoporus is designed to two sections, the thickness of epimere outer wall is greater than the thickness of hypomere outer wall, the diameter of the bottom outlet of exit orifice is equal with the external diameter of endoporus hypomere, like this endoporus hypomere is inserted in bottom outlet, the epimere of endoporus is stuck on bottom outlet just, can play fastening effect equally.
Making-the indirect method of embodiment four reagent device or kit detects mycoplasma pneumoniae antibody
The present invention is simpler based on the technical one of enzyme linked immunosorbent detection, accurately, effective methodology, its ultimate principle adopted is Dot-ELISA: will be adsorbed in solid phase by mycoplasma pneumoniae antigen, by hatch make dilution human serum or blood plasma in specific antibody be combined with antigen, the antibody be not combined with solid phase is removed in washing, add the human immunoglobulins's enzyme connection thing by horseradish peroxidase-labeled, hatch, remove unconjugated enzyme connection thing, add enzyme chromogen substrate, the color produced is directly proportional to the specific antibody concentrations detected in sample.This method is mainly by realizing the immune detection of mycoplasma pneumoniae antibody for the analytical reagent device of enzyme linked immunosorbent detection and matched reagent.By this enzyme-linked immunoassay method, use analytical reagent device and the reagent of particular analysis instrument simultaneously, can be quick, judge accurately and diagnose for adjuvant clinical.
Using position, hole 11 as sample aperture, add liquid sample in use, take for during detection;
Using position, hole 12 as assistant agent hole, detect and add auxiliary reagent (as added adsorbent when detecting IgM) whenever necessary, with sealing film sealing, take for detection;
Using position, hole 13 as enzyme conjugates hole, add enzyme conjugates solution sealing film and seal, take for during detection;
Using position, hole 14 as substrate hole, seal with sealing film after adding tmb substrate solution, during for detection;
Using position, hole 15 as termination fluid apertures, seal with sealing film after adding stop buffer, during for detection;
Using position, hole 16 as dilution fluid apertures, seal with sealing film after adding Sample dilution, during for detection;
Using position, hole 17 as encrusting substance, hole/reacting hole/colorimetric hole, has been coated with mycoplasma pneumoniae antigen, and to annotate liquid sample to be measured and detect reagent and cleansing solution as reaction vessel, carries out absorbance measurement after reaction terminating;
Using position, hole 18 as dilution holes, during for diluted sample;
Be pasted with at handle 20 bar code 30 that mycoplasma pneumoniae antibody detects reagent and analytical equipment information, this bar code comprises test item code, detects the sequence number of reagent product batch number, the reagent term of validity, quantitative measurement standard parameter of curve/qualitative correction coefficient, enzyme linked immunoassay type, reagent and analytical equipment.
Prepare some analytical equipments according to the method described above, prepare corresponding calibration object and Quality Control thing in addition.So namely, constitute complete mycoplasma pneumoniae antibody and measure kit component.By detecting the reagent device of mycoplasma pneumoniae antibody and supporting the use the external packing box of component loading kit, namely make and detect mycoplasma pneumoniae antibody kit.
The detection method of embodiment five mycoplasma pneumoniae antibody IgG
The present patent application provides a kind of method utilizing mentioned reagent device to carry out mycoplasma pneumoniae antibody IgG detection, and described method comprises following step:
1. in described sample aperture, add sample 80 ~ 150 μ L;
2. from dilution fluid apertures, draw 360 μ L liquid in dilution holes with accurate charger;
3. remove the remaining liq in dilution fluid apertures, from dilution holes, draw 180 μ L liquid return dilution fluid apertures;
4. from sample aperture, draw 20 μ L liquid in dilution fluid apertures, the dilution of 10 times, sample with accurate charger;
5. with accurate charger from dilution fluid apertures imbitition 20 μ L in dilution holes, the dilution of 100 times, sample;
6. in reacting hole, at 25 DEG C, after hatching 60min, remove liquid with accurate charger imbitition 100 μ L from dilution fluid apertures;
7. after 3 ~ 5 washings being carried out to reacting hole with cleansing solution, remove liquid;
8. react to reacting hole with anti-human IgG antibodies's enzyme conjugates solution that 100 μ L horseradish peroxidase-labeled drawn by accurate charger from enzyme conjugates hole, at 25 DEG C, after reaction 30min, remove liquid;
9. repeat step 7;
10. to reacting hole, react 10 ~ 15min with the tmb substrate solution that 100 μ L drawn by accurate charger from substrate hole;
11. annotate in reacting hole from the stop buffer stopping drawing fluid apertures 100 μ L with accurate charger, detects, read OD value in 1 ~ 10min under 450nm and 630nm dual wavelength condition.
Embodiment six realizes the analysis operation flow process detected mycoplasma pneumoniae antibody IgG in sample by fully-automatic analyzer
Further, detection method described in the present patent application also comprise corresponding with the use of fully-automatic analyzer, this fully-automatic analyzer comprises an analytical equipment pallet, it overlaps with the matching form of analytical equipment, one has 30 positions can place for analytical equipment, for detecting analysis, comprising the integrated mechano-electronic structure of modular and software control system in addition, the filling of robotization can be realized, dilute, hatch, wash, reading, analytic process.Each position independent quantitative is analyzed, and ensures the accuracy of result.After instrument runs, analytical equipment pallet can turn to different positions voluntarily and annotate, and dilution, hatches, the step of washing and reading.
Concrete operation comprises following step:
(1) preparation of scrutiny program: configure corresponding solution on request, comprise lavation buffer solution, cleaning fluid or thimerosal, prepare in the corresponding liquid bottles of complete loading;
(2) be connected with external computing machine: instrument is connected with external computing machine, thus the acquired results that normally worked by instrument transfers to integrated system process;
(3) start shooting: after opening instrument switch, by the working interface of external computing machine to the self-inspection of instrument designing automatic or manual, thus prepare for the normal operation of instrument;
(4) preheating: after powering, instrument can start heating schedule, and temperature is adjusted to temperature to be checked;
(5) inspection is rinsed;
(6) detection of mycoplasma pneumoniae antibody IgG:
1) from have seal while open the package, take the analytical reagent device of requirement, after deaeration, sack be tamping;
2) solution in Inspection and analysis reagent device tmb substrate hole, should be without color change, otherwise should discard;
3) in the sample aperture of each analytical reagent device, add the undiluted sample of 50 ~ 120 μ L respectively, suggestion adds the sample of 100 μ L, often changes the reagent of a lot number, should get one of them analytical reagent device and calibration object carries out instrument calibration;
4) in analytical equipment pallet, the analytical reagent device of corresponding quantity is put into according to the quantity of required detection, click " beginning ", " scanning ", instrument can automatically scanning analysis reagent device bar code, Quality Control thing bar code and calibration object bar code, then sample is numbered, or by outer strip code scanner, sample bar code is scanned;
5) click " RUN ", instrument runs automatically according to bar code information, and according to bar code, program is testing calibration product first, by calibration, revises typical curve; Secondly Quality Control thing is detected, if its testing result is in the scope indicated, then represents that the typical curve of detection meets the requirements, can be used for the detection of sample, finally start the trace routine of sample;
6) dilute: acupuncture holes position sealing film automatic sucking dilution 360 μ L is in dilution holes in filling, and the remaining liq removed in dilution fluid apertures, from dilution holes, draw dilution 180 μ L again return dilution fluid apertures, filling pin carries out Sample Dilution from sample aperture automatic sucking sample 20 μ L to dilution fluid apertures, 20 μ L are drawn to dilution holes again from dilution fluid apertures, after action completes, moved to reacting hole hatch 30 ~ 60min by the sample diluted pin of being annotated, usual instrument is set as 60min, removes liquid afterwards;
7) wash: flushing needle is drawn after a certain amount of lavation buffer solution carries out three to five washings to reagent wells and removed liquid from corresponding liquid bottle;
8) acupuncture of annotating is broken anti-human IgG antibodies's enzyme conjugates solution that enzyme conjugates hole sealing film draws 100 μ L horseradish peroxidase-labeled and is reacted to reacting hole, and remove liquid after reaction 30 ~ 60min, usual instrument is set as 30min;
9) step 7 is repeated);
10) acupuncture of annotating is broken tmb substrate hole sealing film and is drawn the tmb substrate of 100 μ L to reacting hole reaction 10 ~ 20min, and usual instrument is set as 10min;
11) acupuncture of annotating is broken termination fluid apertures sealing film and is drawn the stop buffer filling of 100 μ L to reacting hole, in 1 ~ 10min, read OD value under 450nm/630nm dual wavelength.
(7) testing result: when trace routine is run complete, by the data processing software analysis on computing machine, finally generates report to consult;
(8) shut down: detect after terminating, before instrument shutdown, must clean cycle be started, can avoid from the residual salt crystallization in fluid path in solution like this, avoid damaging instrument or causing testing result invalid, after having cleaned, instrument power source is closed automatically.
The Quality Control of the detection application of mycoplasma pneumoniae antibody IgG in embodiment seven clinical samples, interpretation of result and detection
Adopt method of operating and the program of embodiment five, use the kit described in embodiment four, can be used for the mycoplasma pneumoniae antibody IgG level in quantitative measurement human serum or blood plasma.
Detect specific antibody in serum and can reflect the infection conditions of pathogen.Mycoplasma pneumoniae antibody IgG occurs may be more late, and the duration is longer, and specificity is stronger.Adjuvant clinical diagnosis can be carried out according to the result detected, tentatively judge the situation of patient, finally make a definite diagnosis and should consider in conjunction with clinical manifestation or other diagnostic method/indexs.
Be below the analysis of testing result:
(1) reference value (term of reference)
Normal reference value: 0 ~ 30AU/mL; Detect the negative sample of some (having statistical significance), (namely the mean value of result add 3 times of standard deviations
) be the upper limit of reference value.
Suitable term of reference can be set up according to actual conditions in each laboratory.
(2) explanation of testing result
If sample value > is 30AU/mL, prompting antibody horizontal raises, but should make a definite diagnosis in conjunction with clinical manifestation or other diagnostic method/indexs.
Conveniently clinical practice, can with reference to following judgment rule:
Sample value < 24AU/mL is negative
24AU/mL≤sample value≤36AU/mL is suspicious
Sample value > 36AU/mL is positive
When testing result is suspicious, should again detect, if be still suspicious, need after 2 ~ 3 weeks Resurvey pattern detection.
Be below that the testing process duplicate detection of embodiment six is positive and negative quality controlled serum, the repeatability of check result, obtains following result:
The detection method of embodiment eight mycoplasma pneumoniae antibody IgM
The present patent application provides a kind of method utilizing mentioned reagent device to carry out mycoplasma pneumoniae antibody detection IgM, and described method comprises following step:
1. in described sample aperture, add sample 80 ~ 150 μ L;
2. from dilution fluid apertures, draw 370 μ L liquid in dilution holes with accurate charger;
3. remove the remaining liq in dilution fluid apertures, from dilution holes, draw 180 μ L liquid return dilution fluid apertures;
4. from sample aperture, draw 20 μ L liquid in dilution fluid apertures, the dilution of 10 times, sample with accurate charger;
5. with accurate charger from dilution fluid apertures imbitition 20 μ L in dilution holes, the dilution of 100 times, sample;
6., when adsorbent adds in assistant agent hole, in reacting hole, when adsorbent adds in dilution fluid apertures together with dilution, then do not need this step with accurate charger imbitition 30 μ L from assistant agent hole;
7. in reacting hole, at 25 ~ 37 DEG C, after hatching 60min, remove liquid with accurate charger imbitition 100 μ L from dilution fluid apertures;
8. after 3 ~ 5 washings being carried out to reacting hole with cleansing solution, remove liquid;
9. react to reacting hole with anti-human IgM antibodies's enzyme conjugates solution that 100 μ L horseradish peroxidase-labeled drawn by accurate charger from enzyme conjugates hole, at 25 ~ 37 DEG C, after reaction 30min, remove liquid;
10. repeat step 8;
11. react 10 ~ 15min with the tmb substrate solution that 100 μ L drawn by accurate charger from substrate hole to reacting hole;
12. annotate in reacting hole from the stop buffer stopping drawing fluid apertures 100 μ L with accurate charger, detects, read OD value in 1 ~ 10min under 450nm and 630nm dual wavelength condition.
Embodiment nine realizes the analysis operation flow process detected mycoplasma pneumoniae antibody IgM in sample by fully-automatic analyzer
Further, detection method described in the present patent application also comprise corresponding with the use of fully-automatic analyzer, this fully-automatic analyzer comprises an analytical equipment pallet, it overlaps with the matching form of analytical equipment, one has 30 positions can place for analytical equipment, for detecting analysis, comprising the integrated mechano-electronic structure of modular and software control system in addition, the filling of robotization can be realized, dilute, hatch, wash, reading, analytic process.The independence qualitative analysis of each position, ensures the accuracy of result.After instrument runs, analytical equipment pallet can turn to different positions voluntarily and annotate, and dilution, hatches, the step of washing and reading.
Concrete operation comprises following step:
(1) preparation of scrutiny program: configure corresponding solution on request, comprise lavation buffer solution, cleaning fluid or thimerosal, prepare in the corresponding liquid bottles of complete loading;
(2) be connected with external computing machine: instrument is connected with external computing machine, thus the acquired results that normally worked by instrument transfers to integrated system process;
(3) start shooting: after opening instrument switch, by the working interface of external computing machine to the self-inspection of instrument designing automatic or manual, thus prepare for the normal operation of instrument;
(4) preheating: after powering, instrument can start heating schedule, and temperature is adjusted to temperature to be checked;
(5) inspection is rinsed;
(6) detection of mycoplasma pneumoniae antibody IgM:
1) from have seal while open the package, take the analytical reagent device of requirement, after deaeration, sack be tamping;
2) solution in Inspection and analysis reagent device tmb substrate hole, should be without color change, otherwise should discard;
3) in the sample aperture of each analytical reagent device, add the undiluted sample of 50 ~ 120 μ L respectively, suggestion adds the sample of 100 μ L, often changes the reagent of a lot number, should get one of them analytical reagent device and calibration object carries out instrument calibration;
4) in analytical equipment pallet, the analytical reagent device of corresponding quantity is put into according to the quantity of required detection, click " beginning ", " scanning ", instrument can automatically scanning analysis reagent device bar code, Quality Control thing bar code and calibration object bar code, then sample is numbered, or by outer strip code scanner, sample bar code is scanned;
5) click " RUN ", instrument runs automatically according to bar code information, and according to bar code, program is testing calibration product first, by single-point calibration, and Criterion curve; Secondly Quality Control thing is detected, if its testing result is in the scope indicated, then represents that the typical curve curve of foundation is qualified, can be used for the detection of sample, finally start the trace routine of sample;
6) dilute: acupuncture holes position sealing film automatic sucking dilution 370 μ L is in dilution holes in filling, and the remaining liq 50 μ L removed in dilution fluid apertures, from dilution holes, draw dilution 180 μ L again return dilution fluid apertures, filling pin carries out Sample Dilution from sample aperture automatic sucking sample 20 μ L to dilution fluid apertures, 20 μ L are drawn to dilution holes again from dilution fluid apertures, 30 μ L adsorbents are drawn in addition in reacting hole from auxiliary reagent hole, after action completes, moved to reacting hole hatch 30 ~ 60min by the sample diluted pin of being annotated, usual instrument is set as 60min, remove liquid afterwards,
7) wash: flushing needle is drawn after a certain amount of lavation buffer solution carries out three to five washings to reagent wells and removed liquid from corresponding liquid bottle;
8) acupuncture of annotating is broken the anti-human IgM antienzyme bond solution body that enzyme conjugates hole sealing film draws 100 μ L horseradish peroxidase-labeled and is reacted to reacting hole, and remove liquid after reaction 30 ~ 60min, usual instrument is set as 30min;
9) step 7 is repeated);
10) acupuncture of annotating is broken tmb substrate hole sealing film and is drawn the tmb substrate of 100 μ L to reacting hole reaction 10 ~ 20min, and usual instrument is set as 10min;
11) acupuncture of annotating is broken termination fluid apertures sealing film and is drawn the stop buffer filling of 100 μ L to reacting hole, in 1 ~ 10min, read OD value under 450nm/630nm dual wavelength.
(7) testing result: when trace routine is run complete, by the data processing software analysis on computing machine, finally generates report to consult;
(8) shut down: detect after terminating, before instrument shutdown, must clean cycle be started, can avoid from the residual salt crystallization in fluid path in solution like this, avoid damaging instrument or causing testing result invalid, after having cleaned, instrument power source is closed automatically.
The Quality Control of the detection application of mycoplasma pneumoniae antibody IgM in embodiment ten clinical samples, interpretation of result and detection
Adopt method of operating and the program of embodiment eight, use the kit described in embodiment four, can be used for the mycoplasma pneumoniae antibody IgM level in qualitative detection human serum or blood plasma.
Detect specific antibody in serum and can reflect the infection conditions of pathogen.Mycoplasma pneumoniae antibody IgM occurs comparatively early, and the duration is longer, and its positive prompting acute stage of infection is the specific index of early diagnosis.Adjuvant clinical diagnosis can be carried out according to the result detected, tentatively judge the situation of patient, finally make a definite diagnosis and should consider in conjunction with clinical manifestation or other diagnostic method/indexs.
Be below the analysis of testing result:
(1) reference value (term of reference)
Normal reference value: 0 ~ 1.0.
(2) explanation of testing result
If sample value > 1.0, prompting antibody horizontal raises, but should make a definite diagnosis in conjunction with clinical manifestation or other diagnostic method/indexs.
Conveniently clinical practice, can with reference to following judgment rule:
Sample value < 0.9 is negative
0.9≤sample value≤1.1 are suspicious
Sample value > 1.1 is positive
When testing result is suspicious, should again detect, if be still suspicious, need after 2 ~ 3 weeks Resurvey pattern detection.
Be below that the testing process duplicate detection of embodiment nine is positive and negative quality controlled serum, the repeatability of check result, obtains following result:
According to the present invention, automatically carry out the detection of many increments mycoplasma pneumoniae antibody originally by identical analytic process simultaneously, and can be associated with other or unconnected project detects simultaneously, this just makes, and detection more simplifies, cost reduces, detection time shortens, cross pollution not easily occurs, detect processing ease carries out; And detect high specificity, highly sensitive, accuracy good.
Claims (3)
1. detect a detection method for mycoplasma pneumoniae antibody, it is characterized in that, described method utilizes reagent device and has the fully-automatic analyzer overlapped with reagent device matching form carries out mycoplasma pneumoniae antibody detection, described reagent device is strip, comprise the matrix with position, eight holes and the handle being positioned at matrix one end, putting in order of position, eight holes is followed successively by sample aperture near handle end, assistant agent hole, enzyme conjugates hole, substrate hole, stop fluid apertures, dilution fluid apertures, reacting hole and dilution holes, sample to be tested is filled in sample aperture, assistant agent hole adds auxiliary reagent whenever necessary for detection, enzyme conjugates solution is filled in enzyme conjugates hole, substrate fills substrate solution in hole, stop filling stop buffer in fluid apertures, dilution is filled in dilution fluid apertures, reacting hole is flat and has high light penetrability, hole endoperidium has mycoplasma pneumoniae antigen, and to annotate liquid sample to be measured and detect reagent and cleansing solution as reaction vessel, absorbance measurement is carried out after reaction terminating, dilution holes is as Sample Dilution container, during for diluted sample,
In described reagent device, assistant agent hole, enzyme conjugates hole, substrate hole, termination fluid apertures and dilution fluid apertures are coated with sealing film; Described reagent device also comprises several support columns, and described support column is arranged in below described reagent device matrix, is separated with position, more than one hole between adjacent supports post; In described reagent device, reacting hole is made up of exit orifice and endoporus, the bottom of exit orifice has bottom outlet, endoporus through bottom outlet and with bottom outlet wringing fit, the outer wall of endoporus is designed to two sections, the thickness of epimere outer wall is greater than the thickness of hypomere outer wall, and the bottom diameter of exit orifice is equal with endoporus hypomere external diameter, is inserted by endoporus hypomere in bottom outlet, the epimere of endoporus is stuck on bottom outlet just, leaves anti-overflow chamber between exit orifice and endoporus; In described reagent device, the mycoplasma pneumoniae antigen of the endoporus bag quilt of reacting hole comprises purifying and the mycoplasma pneumoniae of the mycoplasma pneumoniae of deactivation or restructuring; After described fully-automatic analyzer runs, reagent device pallet can turn to different positions voluntarily and annotate, and dilution, hatches, the step of washing and reading;
Described method comprises following step:
Undiluted sample is added in described sample aperture;
From dilution fluid apertures, draw dilution adds in dilution holes;
Remove the remaining liq in dilution fluid apertures, from dilution holes, draw partially liq return dilution fluid apertures;
From sample aperture, draw sample add in dilution fluid apertures, sample is diluted;
From dilution fluid apertures, imbitition adds in dilution holes, is further diluted by sample;
As detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole from assistant agent hole imbitition, other situations then do not need this step;
From dilution holes, imbitition adds in reacting hole, under the condition of 25 ~ 37 DEG C, hatches 30 ~ 60min;
Liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
From enzyme conjugates hole, draw enzyme conjugates solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, removes liquid after reaction 30 ~ 60min;
Repeat step 8);
From substrate hole, draw substrate solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, and reaction 10 ~ 20min;
From termination fluid apertures, draw stop buffer adds in reacting hole, reads OD value in 1 ~ 10min in 450nm, or Double wavelength method measures, and detects in 1 ~ 10min in 450nm and wavelength coverage under the condition of another wavelength of 620nm ~ 690nm, reads OD value.
2. method according to claim 1, is characterized in that, described method comprises following step:
In described sample aperture, add undiluted sample, volume is at least 1/4 of sample aperture capacity;
From dilution fluid apertures, draw dilution adds in dilution holes, and the amount of absorption is more than 7/10 of total amount of liquid in hole;
Remove the remaining liq in dilution fluid apertures, from dilution holes, draw partially liq according to expection extension rate and return dilution fluid apertures;
From sample aperture, draw sample add in dilution fluid apertures, diluted by sample, extension rate is 1 ~ 10 times;
From dilution fluid apertures, imbitition adds in dilution holes, and further diluted by sample, extension rate is 1 ~ 100 times;
As detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole from assistant agent hole imbitition, other situations then do not need this step;
From dilution holes, imbitition adds in reacting hole, under the condition of 25 ~ 37 DEG C, hatches 30 ~ 60min;
Liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
From enzyme conjugates hole, draw enzyme conjugates solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, removes liquid after reaction 30 ~ 60min;
Repeat step 8);
From substrate hole, draw substrate solution adds in reacting hole, under the condition of 25 ~ 37 DEG C, and reaction 10 ~ 20min;
From termination fluid apertures, draw stop buffer adds in reacting hole, reads OD value in 1 ~ 10min in 450nm, or Double wavelength method measures, and detects in 1 ~ 10min in 450nm and wavelength coverage under the condition of another wavelength of 620nm ~ 690nm, reads OD value.
3. method according to claim 1, is characterized in that, described method comprises following step:
Sample 80 ~ 150 μ L is added in described sample aperture;
From dilution fluid apertures, 360 μ L liquid are drawn in dilution holes with accurate charger;
Remove the remaining liq in dilution fluid apertures, from dilution holes, draw 180 μ L liquid return dilution fluid apertures;
From sample aperture, 20 μ L liquid are drawn in dilution fluid apertures, the dilution of 10 times, sample with accurate charger;
With accurate charger from dilution fluid apertures imbitition 20 μ L in dilution holes, the dilution of 100 times, sample;
As detection mycoplasma pneumoniae antibody IgM and when adding adsorbent in assistant agent hole, add reacting hole with accurate charger from assistant agent hole imbitition 30 μ L, other situations then do not need this step;
To in reacting hole, at 25 ~ 37 DEG C, after hatching 60min, liquid is removed with accurate charger imbitition 100 μ L from dilution fluid apertures;
Liquid is removed after 3 ~ 5 washings being carried out to reacting hole with cleansing solution;
The abzyme bond solution drawing 100 μ L horseradish peroxidase-labeled with accurate charger from enzyme conjugates hole reacts to reacting hole, at 25 ~ 37 DEG C, removes liquid after reaction 30min;
Repeat step 8);
The tmb substrate solution drawing 100 μ L with accurate charger from substrate hole reacts 10 ~ 15min to reacting hole;
Annotate in reacting hole from the stop buffer stopping drawing fluid apertures 100 μ L with accurate charger, detects under 450nm and 630nm dual wavelength condition in 1 ~ 10min, read OD value.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110453956.3A CN103185784B (en) | 2011-12-30 | 2011-12-30 | Reagent device and method for detecting mycoplasma pneumonia antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110453956.3A CN103185784B (en) | 2011-12-30 | 2011-12-30 | Reagent device and method for detecting mycoplasma pneumonia antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103185784A CN103185784A (en) | 2013-07-03 |
| CN103185784B true CN103185784B (en) | 2015-03-18 |
Family
ID=48677062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110453956.3A Active CN103185784B (en) | 2011-12-30 | 2011-12-30 | Reagent device and method for detecting mycoplasma pneumonia antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103185784B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248944A (en) * | 2016-06-30 | 2016-12-21 | 深圳市亚辉龙生物科技股份有限公司 | A kind of CPn IgG chemiluminescence immune detection reagent kit and preparation method thereof |
| CN112485447B (en) * | 2020-11-18 | 2022-09-06 | 中元汇吉生物技术股份有限公司 | Kit for determining complement C1q |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101699290B (en) * | 2009-04-03 | 2013-12-25 | 李克生 | Method for testing mycoplasma pneumoniae antibody (IgG/IgM) gold-labeled quick test card |
| CN201611346U (en) * | 2009-09-17 | 2010-10-20 | 深圳市亚辉龙生物科技有限公司 | Analysis device for enzyme-linked immunity detection |
| CN201993361U (en) * | 2010-12-31 | 2011-09-28 | 深圳市亚辉龙生物科技有限公司 | Reagent device used for detecting anticardiolipin antibody immunoglobulin (IgM) |
-
2011
- 2011-12-30 CN CN201110453956.3A patent/CN103185784B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103185784A (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102147409B (en) | A kind of method measuring Anti-nucleosome antibodies IgG and reagent device | |
| CN102147408A (en) | Method for testing anti-SmD1 antibody IgG and reagent device | |
| CN103185793B (en) | Reagent device for detecting helicobacter pylori antibody and method thereof | |
| CN103384826B (en) | A kind of method and reagent device measuring anti-SARS-coro navirus antibody IgG | |
| CN103185797B (en) | Reagent device and method for detecting anti-myeloperoxidase antibody | |
| CN102147412A (en) | Method for determining antiproteinase 3 antibody IgG (intravenous gamma globulin) and reagent device | |
| CN103185784B (en) | Reagent device and method for detecting mycoplasma pneumonia antibody | |
| CN103185801B (en) | Reagent device and method for detecting anti-beta2 glycoprotein I antibody | |
| CN103185788B (en) | Method for detecting rheumatoid factor | |
| CN103185785B (en) | Reagent device and method for detecting anti-cardiolipin antibody | |
| CN103185800B (en) | Reagent device for detecting anti-cyclic critrullinated polypeptide antibody and method thereof | |
| CN102156190A (en) | Method for detecting anti-beta2 glycoprotein I antibody Ig (Immune globulin) G/A/M and reagent device | |
| CN103185787B (en) | Method for detecting anti-SSA antibody | |
| CN103185782B (en) | Reagent device and method for detecting anti-mitochondrial antibodies type M2 antibody | |
| CN101963618B (en) | Method for identifying heterophilic antibody interference in antibody microarray system and antibody microarray chip using same for detecting target antigen | |
| CN103185777B (en) | Reagent device and method for detecting anti-Jo-1 antibody | |
| CN103185779B (en) | Reagent device for detecting antinuclear antibody and method thereof | |
| CN209400549U (en) | For detecting the immuno-chromatographic test paper strip of saccharification hemoglobin content and comprising its immunoassay detection device | |
| CN103185778B (en) | Reagent device for detecting anti-Sc170 antibody and method thereof | |
| CN103185792B (en) | Reagent device for detecting mumps virus antibody and method thereof | |
| CN103185781B (en) | Reagent device for detecting anti-glomerular basement membrane antibody and method thereof | |
| CN103185786B (en) | Reagent device and method for detecting anti-double-stranded-DNA antibody | |
| CN103185794B (en) | Reagent device and method for detecting varicella-zoster-virus antibody | |
| CN103185780B (en) | Reagent device for detecting anti-U1-snRNP antibody and method thereof | |
| CN103185795A (en) | Reagent device and method for detecting EB virus antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN YHLO BIOTECH CO., LTD. Free format text: FORMER NAME: SHENZHEN YHLO BIOTECH. CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Nanshan District Nanshan street Shenzhen city Guangdong province 518000 Xing Hai Lu Lai Shan Industrial Zone 5 1-4 Patentee after: SHENZHEN YHLO BIOTECH CO., LTD. Address before: 5, 518054, 1-4, Lai Shan Industrial Zone, Shenzhen, Nanshan District, Guangdong Patentee before: Shenzhen Yhlo Biotech. Co., Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 518000 Shenzhen 1 Longgang biological technology plant 1, Baolong two road, Baolong street, Guangdong Patentee after: SHENZHEN YHLO BIOTECH CO., LTD. Address before: 518000 Guangdong, Shenzhen, Nanshan District Nanshan street, Xinghai Road, Li Shan Industrial Zone, 1-4 1-4 floors. Patentee before: SHENZHEN YHLO BIOTECH CO., LTD. |